Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
A peptide based on the complementarity determining region (CDR)1 of a human monoclonal anti-DNA autoantibody (hCDR1) was shown to either prevent or treat an already established murine lupus in systemic lupus erythematosus (SLE)-prone mice or in mice with induced experimental SLE. The present study was undertaken to determine the therapeutic potential of hCDR1 in a model of lupus in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes (PBL) of patients with SLE. To this end, PBL obtained from lupus patients were injected intraperitoneally into two equal groups of SCID mice that were treated either with the hCDR1 (50 micro g/mouse) once a week for 8 weeks, or with a control peptide. Mice were tested for human IgG levels, anti-dsDNA autoantibodies, anti-tetanus toxoid antibodies and proteinuria. At sacrifice, the kidneys of the successfully engrafted mice were assessed for human IgG and murine complement C3 deposits. Of the 58 mice transplanted with PBL of SLE patients, 38 (66%) were engrafted successfully. The mice that were treated with the control peptide developed human dsDNA-specific antibodies. Treatment with hCDR1 down-regulated the latter significantly. No significant effect of the treatment on the levels of anti-tetanus toxoid antibodies could be observed. Treatment with hCDR1 resulted in a significant amelioration of the clinical features manifested by proteinuria, human IgG complex deposits as well as deposits of murine complement C3. Thus, the hCDR1 peptide is a potential candidate for a novel specific treatment of SLE patients.
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
N
N
Mauermann
Z
Z
Sthoeger
H
H
Zinger
E
E
Mozes
D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D001323:Autoantibodies / Q000276:immunology*; D003176:Complement C3 / Q000032:analysis; D022801:Complementarity Determining Regions / Q000008:administration & dosage* / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D008214:Lymphocytes; D051379:Mice; D016513:Mice, SCID; D011507:Proteinuria; D013745:Tetanus Toxoid / Q000276:immunology
D001323:Autoantibodies; D003176:Complement C3; D022801:Complementarity Determining Regions; D016207:Cytokines; D007074:Immunoglobulin G; D013745:Tetanus Toxoid